SCHEMBL3384953

SCHEMBL3384953

CN(C)c1nc(NCc2ccccn2)c2c(-c3ccc(F)cc3)csc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.57
TNF P01375 2/20 0.56
NOD1 Q9Y239 2/20 0.56
MAPK1 P28482 1/20 0.56
KCNA5 P22460 11/20 0.49
PIP4K2C Q8TBX8 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ESR1 P03372 1/20 0.43
JAK2 O60674 2/20 0.41
CDK2 P24941 2/20 0.41
TYK2 P29597 2/20 0.41
GSK3B P49841 2/20 0.41
JAK3 P52333 2/20 0.41
BTK Q06187 2/20 0.41
AURKB Q96GD4 2/20 0.41
IRAK4 Q9NWZ3 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369089 0.92 KCNH2 (0.67) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL3386430 0.88 TNF (0.53) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL3386735 0.87 TNF (0.59) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL2368786 0.85 TNF (0.57) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL3385334 0.85 ESR1 (0.61) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL2368795 0.85 TNF (0.59) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL2368683 0.82 TNF (0.56) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL2368804 0.82 TNF (0.55) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL2369260 0.82 TNF (0.55) KCNH2TNFNOD1MAPK1KCNA5
SCHEMBL3387956 0.81 TNF (0.83) TNFNOD1MAPK1KCNA5PIP4K2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP claimed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US claimed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO claimed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 KCNH2 6/4885TNF 2689/4885NOD1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.